3 bucks new rv rate

1.) " in the interest of Iraq and its people ” 2.) " if the relations are not for the country’s interest, “I do not like and do not welcome any partnership with any party.” say what? did i hear that right? wow I really can't believe what Malarki said? did Malarki and his cronies really really care about ordinary iraqi citizens? it is full of crap and another BS coming out of Malarki's mouth. since when do Malarki and his cronies care about iraqi citizens? as we all know that Malarki and his cronies only care about their own fat pockets.

the last devaluation was from 1190 to 1460 back in December 20, 2020. if they want to return to previous rate 1190, why do they have to wait until now year 2022 ( more than 1 year since the last devaluation in December 20. 2020 )? Actually, if they want to return to previous rate 1190, they can do it at any time, don't have to wait more than 1 year to do it. Actually, they can return to previous rate 1190 immediately since the first day the protest began because of the devaluation back in December 2020 that make the price of all goods very expensive and ordinary Iraqi citizens can't afford to buy the basic necessity..

now we have 2 frank, which one is the real frankie and which one is fake?? come on frankie. Hot?? Hot babe or cold shower? of course, it is hot in the desert frankie.

again we can only hope that Al-Kazemi will reinstate the dinar ( which Shabibi couldn't have done it before ) during his second term as a new PM.

(NEXSTAR) – As hospitals nationwide continue struggling to operate during the omicron surge, a variant inside the variant is now raising concerns. Monday, Newsweek reported at least 92 cases of the BA. 2 omicron subvariant have been detected in over 20 U.S. states, including California and Texas. Is headache a symptom of the omicron COVID variant? The omicron variant is made up of three main substrains, BAs 1-3, and until Dec. 23 the World Health Organization said 99% of cases sequenced were BA. 1, Fortune reports. Last week, the subvariant overtook BA. 1 as the dominant substrain in Denmark in just two weeks. BA. 2 went from accounting for 20% of cases to accounting for 45%. Similar increases are now being seen in the U.K. and elsewhere. Modeling by Dr. JP Weiland shows BA. 2 cases grew 90-120% faster than BA. 1, based on Danish numbers. Weiland says data doesn’t yet confirm whether increased spread is because of higher transmissibility or increased immune escape by BA. 2. “BA. 2 is the omicron sibling to watch,” Cornelius Roemer, a computational biologist at Switzerland’s University of Basel tweeted Monday. “It started out later than BA. 1 but has been picking up pretty much everywhere I’ve looked. Don’t think I’ve found a single country where BA. 2 has gone down over time significantly.” Some experts say BA. 2 also shows possibilities of reinfection in people who only recently had BA. 1 omicron. Why is it called ‘stealth’? BA. 2 is somewhat sneakier than the already sneaky BA. 1, hence its name. In addition to its speed, BA. 2 doesn’t have a mutation that BA. 1 had – a deletion in the spike gene – which made that strain easier to identify as omicron on PCR tests. Despite some rumors, this doesn’t mean it can’t be detected, however. Will omicron end soon? Florida epidemiologist says endemic phase is near "BA.2 is detectable by PCR…Depending on the PCR test used it may not look like BA.1 (the other omicron). But it will still give a positive result,” Roemer tweeted. "[It’s] frustrating to see falsehood about non-detectability still around.” Should we be worried? Danish officials say not just yet – especially given hospitalization numbers. "Initial analysis shows no differences in hospitalizations for BA.2 compared to BA.1," Denmark's Statens Serum Institut said in a statement. "It is expected that vaccines also have an effect against severe illness upon BA.2 infection." But Dr. Eric Feigl-Ding, Federation of American Scientists epidemiologist, says swift action to quell transmission in the U.S. is needed – especially given early signs it could cause re-infection in those who’ve just recovered from BA. 1, which he calls “vanilla omicron.” “Denmark’s CDC scientists warns specifically about this risk,” Feigl-Ding tweeted Monday. “This is why mass infection herd strategy is extremely poor choice. And why stopping transmission is critical… The coronavirus doesn’t screw around. If a new variant wins over the previous – you know it’s more aggressive in some way or another.” Despite quick spread, many experts say it’s still too early to know if BA. 2 will cause more severe illness than omicron. link : https://www.msn.com/en-us/health/medical/what-is-e2-80-98stealth-omicron-new-covid-19-sub-variant-seen-in-20-states/ar-AAT8Aw0

Covid-19: New variant imminent – Clinical Microbiologist Source: Blessed Sogah 20 January 2022 2:28pm Dr Michael Owusu “What we have to be looking out for is perhaps another variant, so if a new variant comes in that is much stronger than Omicron, then we start the cycle again but for now, it is still Omicron.” Speaking on The Pulse on Wednesday, the Virologist noted that research is still underway to examine the potential new variant after reports emerged that scientists in France have identified another worrying new variant having 46 mutations. His warning comes in the wake of indications from the head of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus that the worst of the Omicron variant of Covid-19 is over. Tedros, at a news conference, noted that “vaccines may be less effective at preventing infection and transmission of Omicron than they were for previous variants, but they still are exceptionally good at preventing serious disease and death.” Dr Michael Owusu, therefore, advised health authorities to shore up vaccination and to ensure strict enforcement of the safety protocols. Last Tuesday, the Director-General of the Ghana Health Service (GHS), Dr. Patrick Kuma-Aboagye, told the Ghana News Agency that the Service has developed a booster policy, which would soon be made known to the public. According to him, the Service will soon start administering Covid-19 booster shots to stem the spread of the disease in the country. The purpose of a Covid-19 booster shot is to give people an added level of protection from Covid-19 if their existing protection has waned over time. link : https://www.myjoyonline.com/covid-19-new-variant-imminent-clinical-microbiologist/

COVID-19: New Omicron sub variant discovered in Israel The sub variant is thought to have originated in India, and has been found in Canada, Denmark, Singapore, China and Australia. By JERUSALEM POST STAFF Published: JANUARY 13, 2022 21:30 Updated: JANUARY 14, 2022 07:24 Scanning electron microscope image shows SARS-CoV-2, also known as novel coronavirus Some 20 cases of a new sub-variant that developed from the original Omicron variant have been discovered in Israel, KAN reported on Thursday evening. The sub-variant, known as BA2, was discovered during genetic sequencing of sample COVID patients. It contains more mutations than the original Omicron and may be more violent. However, the danger posed by the new sub-variant is still uncertain, and the Health Ministry's coronavirus outreach headquarters clarified that there was no evidence that BA2 behaved differently than Omicron. BA2 was first seen in China a few weeks ago, and is suspected to have originated in India. It has also been observed in Denmark, Australia, Canada and Singapore, Kan reported. Scientists quoted in KAN's report said they were concerned about this new development. Over the past 10 days, Israel has continuously hit a new record of virus carriers, increasing from 12,000 a day to 48,000, with experts believing that the real number of those infected is likely to be much higher. Clalit Health Services Medical worker conduct tests on PCR samples to determine if they are positive for covid-19 at a Clalit Health Services laboratory in Jerusalem The number of serious patients, while still limited, has also started to increase. There were 283 patients on Thursday compared with 136 a week earlier. In addition, 284 new patients were classified as serious over the previous seven days, marking an increase of 189% over the previous week. However, the general situation of Omicron patients appear to be much better than in previous waves. If the new sub-variant is indeed more violent than Omicron, this may cause more severe illness and raise the number of serious patients in hospital. It is being tracked by Israeli and international researchers. link : https://www.jpost.com/breaking-news/article-692495

New sub-variant of Omicron under investigation as it sweeps Europe As most countries surpass their peak of the Omicron wave, scientists are investigating a subtype that may be more transmissible than the original. Brooke Rolfe January 23, 2022 - 1:42AM A new sister subtype of the Covid Omicron variant, which may be more transmissible and harder to track, has begun rearing its head overseas in recent days. The subtype is being referred to as BA. 2, while the original Omicron, currently sweeping through Australia, is known by scientists as BA. 1. While cases of the BA. 2 type of Omicron remain low across various European countries, it could be just a matter of time before it arrives in Australia. Scientists are still however working to determine whether the subtype, which had infected 53 people in the UK up to January 10, is more severe than the original BA. 1 type. While the Health Security Agency has designated BA. 2 as a variant under investigation, its UK incident director Dr Meera Chand said such subtypes were to be expected. “It is the nature of viruses to evolve and mutate, so it’s to be expected that we will continue to see new variants emerge,” she said, according to Metro. Medical staff tend to a Covid patient There had been early indications the BA. 2 type may be more transmissible than BA. 1, however in Denmark, where it accounts for about half of Omicron cases, no stark differences in hospitalisations had yet been noted. Denmark’s Statens Serum Institute this week said it was likely vaccines had an effect against severe BA. 2 infections, which had several differences to BA.1. One difference was that BA. 2 had shown positive for the S-gene, while BA. 1 did not. The lack of S-gene in BA. 1 was a key component in tracking Omicron’s early spread, as it was a feature that distinguished it from Delta. The same feature however may be what makes BA. 2 infections harder to track. Scientists are still confident it will be picked up in certain tests though. Virologist from the Imperial College of London, Tom Peacock, said while early trends suggested BA. 2 was more transmissible, more research was required. “BA. 2 appears to be the major Omicron lineage in (part of) India and the Philippines and there is evidence it is growing compared to BA. 1 in Denmark, the UK and Germany,” one recent tweet read. “Consistent growth across multiple countries is evidence BA. 2 may be some degree more transmissible than BA.1. This is the main reason BA. 2 is currently in the news. “Unfortunately this is really where the evidence mostly ends – we do not currently have a strong handle on antigenicity, severity or a much evidence for how much more transmissibility BA. 2 might have over BA. 1 – however we can make some guesses/early observations.” He added how “very early observations” from India and Denmark suggested there was no dramatic difference in severity when compared to BA.1. “This data should become more solid (one way or another) in the coming weeks,” he said. Mr Peacock also predicted BA. 2 would not have a “substantial” impact on the Omicron wave, which he expected was past its peak already in many countries. link : https://www.news.com.au/world/coronavirus/global/new-subvariant-of-omicron-under-investigation-as-it-sweeps-europe/news-story/fd541ce703a1f04249da30ac7e9f336f

Stealth omicron: New COVID-19 sub-variant seen in 40 countries January 24, 2022 at 10:09 am EST By Debbie Lord, Cox Media Group National Content Desk A sub-variant of the omicron strain of the COVID-19 virus appears to be on the rise in at least 40 countries, according to the World Health Organization. The “stealth” omicron variant, as some scientists are calling it, can be difficult to identify because it lacks a genetic characteristic that scientists use to identify the original omicron variant. According to the WHO, omicron, which is known as B.1.1.529, has three subvariants: BA.1, BA.2, and BA.3. As of a few days before Christmas, BA.1 was responsible for more than 99% of the cases the organization sequenced. Now, the WHO says, BA.2 could be on the rise, competing with BA.1. The subvariant has been found in increasing numbers in Norway, according to the country’s public health officials. Cases of BA.2 went from seven detections as of Jan. 4 to 611 cases by Jan. 19. While the original omicron variant, known as BA.1, is considered very contagious by health care officials, the subvariant could be even more contagious, researchers say. In Denmark, BA.2 now makes up almost half of all omicron cases, health officials there have said. It is not yet known if BA.2 is more deadly than the original omicron variant, though researchers in Denmark say they have not seen a difference in hospitalizations or deaths. “Initial analysis shows no differences in hospitalizations for BA.2 compared to BA.1,” according to Denmark’s Statens Serum Institut, a government-run infectious disease research center. Anders Fomsgaard, a researcher at Statens Serum Institut, said scientists are not yet sure why the subvariant seems to be spreading so quickly. “It may be that it is more resistant to the immunity in the population, which allows it to infect more. We do not know yet,” he told broadcaster TV 2. The United Kingdom’s Health Security Agency said it is investigating the new variant as a “variant under investigation” because of the increasing number of cases in the country and around the world. As of Monday morning, a total of 12,842 gene sequences, or samples that were determined to be BA.2, had been uploaded to the GISAID database from around the world. GISAID is an initiative that promotes the sharing of genomic sequencing and other data on influenza and coronaviruses. Of that number, 67 were reported from the United States. link : https://www.wftv.com/news/trending/stealth-omicron-new-covid-19-variant-seen-40-countries/6UZ5IK2JSJGSZKDEPE3EYAVYUM/

may be they still negotiate for a power sharing and money sharing among each other. if a power sharing and a money sharing are not equally fair among each other, then they will delay and delay again to form the official new government. and i guess that works also when electing for official new PM cause we still don't know who the official new PM is until right now.

can anyone see and compare the differences between the picture of the 1 dinar notes above from Nader from mid east and below ( year 1984 and 1992 )? can anyone guess what year 1 dinar note from " Nader from mid east " above? may be someone or member here can read Arabic language and will be able to translate it into English. link : https://www.banknotes.com/iq.htm 1 DINAR 1984 1 dinar 1992

oh ok. thanks stelardoc.

it looked like 1 dinar bkeiller, but i don't know and just wonder, was this 1 dinar note supposed to be a new or old lower denoms? and I wish there is someone can read Arabic language that can tell us the year this note was printed. . I wish someone expert in foreign banknotes can tell us.

just wonder, by any chance and out of curiosity, is this guy's nick name Nader From The Mid East ( in the rumor section )? is this some kind of coincidence or a joke? *** Nader From The Mid East [TV Report] Today in the Iraqi TV news (it's good news, but I'm not sure what they're doing) they said the rate is gonna change when they open the budget...But they keep saying to the "previous". The previous for us it's 1150, 1160, 1170 I don't remember exactly what it is, but they're saying that. When they say previous it mean the previous like that one before, it was corrected? Maybe I'm wrong...I hope they talk about 2003 or 2002 when it used to be $3.35 - $3.40...everybody is talking about it too in the cafe this morning...even if they put it out at 1150 and it floats it will go quick...two or three month would be a $1.50 - $2.00 something like that

now, that's funny. by the way, what are the differences between guru and a pumper? does the guru and pumper ( making money in disguise ) do the same job as dinar dealer?

" namely the fixed exchange rate and the flexible exchange rate ", just wonder which method of exchange rate does Iraq belong to in order to rv the IQD? which method of exchange rate is the best ( win-win solution ) for Iraqi citizens ( more purchasing power ) and also dinar investors ( RV the IQD)?

let's just wait and see if he was right about the date. for me, the first most important thing is the exact date. then, the second is the rate. not the other way around.

Covid antiviral pill launched at Rs 1,399 for full 5-day course Rupali Mukherjee 04-01-2022 MUMBAI: Molnupiravir, the antiviral drug which recently got emergency use approval for treatment of mild to moderate Covid-19 in India, was launched on Monday at Rs 1,399 for the full five-day course, making it one of the cheapest antiviral coronavirus therapies during the pandemic. Over a dozen companies, including Hetero, Sun Pharma, Natco and Dr Reddy’s are in the process of rolling out the oral therapy developed by Merck and and its partner, Ridgeback Biotherapeutics, at prices ranging between Rs 1,500 and Rs 2,500 for the complete treatment, sources told TOI. The antiviral pill is being considered a potential gamechanger globally in Covid treatment as remdesivir used till now is administered intravenously, and in hospital settings. Mankind Pharma, which has tied up with BDR Pharmaceuticals. introduced its antiviral Molulife (200 mg) in Delhi and certain other parts of the country on Monday, a company official said. Further, Sun Pharma has priced the antiviral at around Rs 1,500 for the full course, and is making its ‘Molxvir’ available in markets where there are more cases, and gradually across India. The recommended dose of molnupiravir is 800 mg twice a day for five days. Given the stiff competition among the market players, the treatment cost will remain competitive and affordable for patients, experts said. Molnupiravir, is also the first oral anti-Covid pill approved by UK’s drug regulator, while recently the US Food and Drug Administration cleared it for the treatment of mild-to-moderate Covid-19 in adults, and for those who are at a high risk for progression to severe disease, including hospitalisation or death. Post the USFDA nod, Drugs Controller General of India granted permission for restricted use of molnupiravir for treatment of adult patients with SpO2 93%, and who have high risk of progression of the disease. Earlier in June, MSD signed licensing agreements with five generic companies including Sun Pharma, Cipla, Torrent, Emcure and Dr Reddy’s to manufacture and supply molnupiravir in India, and to over 100 low and middle-income countries. link : https://www.msn.com/en-in/news/other/covid-antiviral-pill-launched-at-rs-1399-for-full-5-day-course/ar-AASoxlm

Indonesia starts COVID boosters for elderly, others at risk EDNA TARIGAN and FADLAN SYAM January 12, 2022 JAKARTA, Indonesia (AP) — Indonesia kicked off a COVID-19 booster campaign for the general public on Wednesday, prioritizing third shots for the elderly and people with compromised immune systems. The government hopes to provide 21 million booster shots in January to people who received their second jabs at least six months ago. Some 117 million people in Indonesia have already received two doses of the vaccine. “This effort is important to increase the immunity of society, considering the COVID-19 virus keeps mutating,” President Joko Widodo said Tuesday. Indonesia has reported more than 4.2 million cases and more than 144,000 deaths since the pandemic began. During the peak of the last surge in July, the country recorded 56,757 cases per day as hospitals were overwhelmed by sick patients and ran out of beds and oxygen supplies. The country provided the Moderna vaccine as a booster for healthcare workers starting in July last year. Indonesia’s Food and Drug Authority on Monday approved emergency-use authorization for the Sinovac, Pfizer, AstraZeneca, Moderna and Zifivax vaccines, all of which will be used as booster shots. Several other vaccines are also being examined for emergency-use authorization. Indonesia’s Health Minister Budi Gunadi Sadikin said the government would consider the availability of vaccines in determining which boosters people will receive and that the boosters might be different from what people received in their first two doses. People who received the Sinovac vaccine as their primary doses will receive half a dose of the Pfizer vaccine or half a dose of the AstraZeneca vaccine as a booster, while those who received AstraZeneca’s vaccine as their primary doses will receive half a dose of the Moderna vaccine as a booster. link : https://news.yahoo.com/indonesia-starts-covid-boosters-elderly-033557654.html?fr=sycsrp_catchall

Only firm licensed to manufacture Molnupiravir in Vietnam 21/01/2022 13:10 The Medicine Patent Pool (MPP) on January 20 announced it has granted licenses to manufacture the COVID-19 treatment drug Molnupiravir to 27 pharmaceutical firms worldwide, including Stella Vietnam (Stellapharm). The antiviral drug molnupiravir is given to mild F0 cases for COVID-19 treatment. A Stella Vietnam representative confirmed the news with tienphong.vn. Besides Stella Vietnam, the MPP also granted its licenses to 10 companies in India, five in China, three in the Republic of Korea, two each in South Africa and Bangladesh, and one each in Egypt /Jordan, Kenya, Pakistan and Indonesia. The MPP website says MPP has signed agreements with 27 generic manufacturing companies for the manufacturing of the oral COVID-19 antiviral medication molnupiravir and supply in 105 low- and-middle-income countries (LMICs). The sublicence agreements are the result of the voluntary licensing agreement signed by MPP and MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA, in October 2021 to facilitate affordable global access for Molnupiravir, that MSD is developing in partnership with Ridgeback Biotherapeutics. “We are encouraged by the large number of new and existing partners that have moved quickly to secure a sublicence for molnupiravir through MPP,” said Charles Gore, MPP Executive Director. “This is a critical step toward ensuring global access to an urgently needed COVID-19 treatment and we are confident that, as manufacturers are working closely with regulatory authorities, the anticipated treatments will be rapidly available in LMICs.” Molnupiravir, the antiviral drug, has been approved for treating COVID-19 patients with mild to moderate symptoms. Studies show the medication can help reduce the numbers of hospitalisations and deaths in COVID-19 patients. In Vietnam, the Ministry of Health has approved a pilot programme using Molnupiravir to treat COVID-19 cases at home. Preliminary reports show almost 100% of patients taking the drug had a low viral load, a very low rate of severe disease, and no deaths. link : https://vietnamnet.vn/en/society/only-firm-licensed-to-manufacture-molnupiravir-in-vietnam-810602.html

Natco Pharma gets non-exclusive licence to manufacture, sell anti-COVID pill Molnupiravir 18 hours ago Sunil Matkar Natco Pharma gets non-exclusive licence to manufacture, sell anti-COVID pill Molnupiravir Drugmaker Natco Pharma Ltd on January 20 announced it has inked an agreement with the Switzerland-based Medicines Patent Pool (MPP) for a non-exclusive license to manufacture and sell anti-COVID pill Molnupiravir. The deal was signed with MPP as it has taken licence from the US-based Merck Sharp & Dohme Corp (MSD) - which has developed Molnupiravir - for the same, the company said in a statement. "Natco with this license agreement can manufacture and sell Molnupiravir Capsules 200 mg. for Indian market, which will be sold under brand name MOLNUNAT ® for treatment of COVID-19 infection with Sp02>93% and who have a high risk of progression of the disease including hospitalisation or death," it added. This agreement allows Natco to expand access to COVID-19 medicines in 105 countries in generic name. Under the licence, the pharmaceutical firm can set its own price for the generic products it produces, paying a royalty on sales to MSD. "MSD, Ridgeback Biotherapeutics and Emory University will not receive royalties for sales of Molnupiravir under this agreement for as long as COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization," Natco clarified. Molnupiravir was cleared for emergency use on December 28 by the Drug Controller General of India (DCGI). Earlier, the anti-COVID pill was cleared for restricted use by the UK drug regulator on November 4 and was subsequently approved for emergency use in the United States. The Indian Council of Medical Research, however, has so far not included Molnupiravir in the clinical management protocol for COVID-19 due to safety concerns. The Union health ministry on January 12 said the drug has risks and warrants caution in use. According to Merck, which released data on Molnupiravir's trials in October, the drug demonstrated highly promising results in reducing viral load to almost zero in merely five days of treatment duration. link : https://www.msn.com/en-in/money/topstories/natco-pharma-gets-non-exclusive-licence-to-manufacture-sell-anti-covid-pill-molnupiravir/ar-AASYhY4

Thailand, Indonesia to develop Covid-19 pill 14 JAN 2022 AT 18:44 An experimental Covid-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Thailand's Public Health Minister Anutin Charnvirakul said on Friday the country planned to develop the anti-viral pill molnupiravir to combat Covid-19 infections amid rising infections driven by the Omicron coronavirus variant. The molnupiravir Covid-19 treatment pill for adult patients at risk of developing severe illness was jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics. The Southeast Asian nation intends to join other countries in the region also planning to make versions of the drug, including Bangladesh and India. "For molnupiravir, the Government Pharmaceutical Organization has plans to co-develop (this drug) with the Chulabhorn Research Institute," Mr Anutin told a news conference. "A committee will research and produce the reactants, which will be additional support for future events," he said. Separately, Indonesia's health minister Budi Gunadi Sadikin said on Friday the country also planned to develop molnupiravir in partnership with pharmaceutical company PT Amarox Pharma Global starting in April or May. Indonesia approved molnupiravir for emergency use this week and 400,000 pills have arrived. Thailand has ordered 50,000 courses of molnupiravir from Merck and was still in discussion with Pfizer for 50,000 courses of its drug Paxlovid. link : https://www.bangkokpost.com/thailand/general/2247635/thailand-and-indonesia-unveil-plans-to-develop-molnupiravir-covid-19-pill

Bill Gates Until Rockefeller Suddenly ‘Letter’ Jokowi January 19, 2022 Jakarta, CNBC Indonesia – Dozens of social foundations belonging to global tycoons, including the Rockefeller Foundation and the Bill Gates Foundation, have been writing letters to President Joko Widodo (Jokowi). The news was conveyed directly by the Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan, after meeting President Jokowi on Tuesday night, (18/1/2022). “There are dozens of large world foundations. For example, Rockefeller, Bill Gates, all of them wrote letters to the President, I was given a copy last night,” said Luhut, Wednesday (1/19/2022). So, what is the content of the letter from the founders of the leading foundation to Jokowi? Luhut said the contents of the letter were asking Jokowi for permission to gather in Bali in April 2022. They intend to hold an event to help Indonesia in dealing with climate change. “The president asked me last night, ‘Mr. Luhut, why did they come?’, ‘I don’t know either, sir’. But they asked if the President was willing to meet them later,” said Luhut, imitating his conversation with Jokowi. Jokowi, said Luhut, also expressed his willingness to attend. Moreover, the event not only discussed the issue of climate change but also related to plastic waste, and efforts to help national MSMEs. “If there are MSMEs, I am ready, Mr. Luhut. One, two days is okay’. So you can imagine the attention of the President, and the attention of the world,” said Luhut. link : https://www.archytele.com/bill-gates-until-rockefeller-suddenly-letter-jokowi/

Bill Gates Until Rockefeller Suddenly ‘Letter’ Jokowi 2 days ago Bill Gates Until Rockefeller Suddenly ‘Letter’ Jokowi Jakarta, CNBC Indonesia – Dozens of social foundations belonging to global tycoons, including the Rockefeller Foundation and the Bill Gates Foundation, have been writing letters to President Joko Widodo (Jokowi). The news was conveyed directly by the Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan, after meeting President Jokowi on Tuesday night, (18/1/2022). “There are dozens of large world foundations. For example, Rockefeller, Bill Gates, all of them wrote letters to the President, I was given a copy last night,” said Luhut, Wednesday (1/19/2022). So, what is the content of the letter from the founders of the leading foundation to Jokowi? Luhut said the contents of the letter were asking Jokowi for permission to gather in Bali in April 2022. They intend to hold an event to help Indonesia in dealing with climate change. “The president asked me last night, ‘Mr. Luhut, why did they come?’, ‘I don’t know either, sir’. But they asked if the President was willing to meet them later,” said Luhut, imitating his conversation with Jokowi. Jokowi, said Luhut, also expressed his willingness to attend. Moreover, the event not only discussed the issue of climate change but also related to plastic waste, and efforts to help national MSMEs. “If there are MSMEs, I am ready, Mr. Luhut. One, two days is okay’. So you can imagine the attention of the President, and the attention of the world,” said Luhut. link : https://news.fox-24.com/news/270140.html

Bill Gates Until Rockefeller Suddenly ‘Letter’ Jokowi January 19, 2022 Jakarta, CNBC Indonesia – Dozens of social foundations belonging to global tycoons, including the Rockefeller Foundation and the Bill Gates Foundation, have been writing letters to President Joko Widodo (Jokowi). The news was conveyed directly by the Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan, after meeting President Jokowi on Tuesday night, (18/1/2022). “There are dozens of large world foundations. For example, Rockefeller, Bill Gates, all of them wrote letters to the President, I was given a copy last night,” said Luhut, Wednesday (1/19/2022). So, what is the content of the letter from the founders of the leading foundation to Jokowi? Luhut said the contents of the letter were asking Jokowi for permission to gather in Bali in April 2022. They intend to hold an event to help Indonesia in dealing with climate change. “The president asked me last night, ‘Mr. Luhut, why did they come?’, ‘I don’t know either, sir’. But they asked if the President was willing to meet them later,” said Luhut, imitating his conversation with Jokowi. Jokowi, said Luhut, also expressed his willingness to attend. Moreover, the event not only discussed the issue of climate change but also related to plastic waste, and efforts to help national MSMEs. “If there are MSMEs, I am ready, Mr. Luhut. One, two days is okay’. So you can imagine the attention of the President, and the attention of the world,” said Luhut. link : https://www.world-today-news.com/bill-gates-until-rockefeller-suddenly-letter-jokowi/